4-异丁酰基庚二酸及3,3-二氰乙基-2,4-己二酮的环合反应

等由酮的一氰乙基化产物水解后得到的δ-酮酸,在大量乙酐或者乙酰氯存在下合成了不饱和δ-内酯.我们用4-异丁酰基庚二酸(1)在过量醋酸酐及乙酰氯存在下回流5h得到7-氧代-8,8-二甲基-△~9-六氢香豆素(2).     

辛弗林衍生物的合成

以苯甲醚为起始原料,与乙酰氯发生付-克酰基化后脱甲基得到4-羟基苯乙酮,然后与液溴进行α-溴代得到2-溴-1-(4-羟苯基)乙酮,再与叔丁胺进行胺化得到1-(4-羟基苯基)-2-(叔丁基氨基)乙酮,最后用氢硼化钠还原合成目标产物1-(4-羟基苯基)-2-(叔丁基氨基)乙醇,总收率约为42.3%。     

β-二酮二氰乙基化合物的酮解反应

甲基酮与丙烯腈反应可以得到一氰乙基、二氰乙基或多氰乙基化产物。据文献报道,丙酮与丙烯腈反应可以得到少量的4-乙酰基庚二腈,产率约为3.7％,其他4-酰基庚二腈的合成方法还未见报道。我们发现由β-二酮的氰乙基化反应得到的β-二酮二氰乙基化产物1a～c,在碳酸钠水溶液中酮解可以得到4-酰基庚二腈2a～c,产率为59～82％。如果1a～c在氢氧化钾水溶液中水解,则得4-酰基庚二酸3a～c。2a～c与2,4-二硝基苯肼反应得到了相应的苯腙4a～c,2a～c经KOH水解亦得3a～c。     

光学活性3-(1′-羟基乙基)-4-乙酰氧基-β-内酰胺的立体选择性合成

(1′R,3R,4R)-N-取代-3-(1′-羟基乙基)-4-乙酰氧基-β-内酰胺(3)是合成青霉烯和碳青霉烯类β-内酰胺抗生素的关键中间体.以廉价的L-抗坏血酸为原料,制得S-缩异丙氧叉甘油醛(5),与胺反应定量转变成相应的手性亚胺(6a～6d),6与双烯酮[2+2]环加成反应,高立体选择性地合成3(S)-乙酰基-β-内酰胺(Sa～8d),其非对映体过量由类似反应的80％提高到接近100％.8a经四步反应得到目标化合物3a.     

1,3-二取代-2-硫代咪唑啉-4-酮的合成

1-苯甲酰基-3-芳基硫脲与氯乙酰氯反应合成了1-芳基-3-苯甲酰基-2-硫代咪唑啉-4-酮,与二氯乙酰氯反应合成了1-芳基-3-苯甲酰基-5-氯-2-硫代咪唑啉-4-酮,与三氯乙酰氯反应时仅得到了硫脲的分解重组产物苯甲酰基芳胺.产物结构经红外光谱、核磁共振谱和高分辨质谱表征.     

由N-酰基-a-氨基酸合成5(4H)-噁唑酮的新方法

在碳酸钾、丙酮的水溶液中由N-酰基四氢噻唑-2-硫酮进行氨基酸解得到10种N-酰基-α-氨基酸Ⅰ_a-j发现在三聚氯氰及三乙胺存在下,由N-酰基-α-氨基酸环合成8种饱和5(4H)-噁唑酮Ⅱ_a-h的新方法,进而在硫酸铁催化下得到10种不饱和5(4H)-噁唑酮衍生物Ⅲ_a-j     

金属钐作用下α,α′-二溴代烷基酮与1,3-二烯的[3 4]环加成反应

α,α′-二溴代烷基酮与环状共轭二烯烃(环戊二烯,呋喃)在金属钐粉和磺化亚铜(10％)作用下,高产率地得到[3 4]环加成产物。与开链共轭二烯烃作用没能得到环加成产物,却高产率地得到α,α′-二溴代烷基酮自身偶合产物环戊烯酮衍生物。     

3,4-二氢-1-(4-哌啶基)-2(1H)-喹啉酮的合成

以苄胺为原料,经6步反应得到新型抗高血压药OPC-21268的中间体3,4-二氢-1-(4-哌啶基)-2(1H)-喹啉酮,总收率13．9％．     

无溶剂、无催化剂条件下5-[(3-吲哚基)-芳甲基]-2,2-二甲基- 1,3-二氧六环-4,6-二酮的合成

在无溶剂和催化剂条件下,由芳香醛、吲哚、丙二酸亚异丙酯的三组分缩合反应,制备了5-[(3-吲哚基)-芳甲基]-2,2-二甲基-1,3-二氧六环-4,6-二酮,产率为70%～85%,产物结构经1H NMR,IR确证.     

微波辐射下离子液体催化一锅三组分反应合成3-{1-[2-(4-芳基噻唑-2-基)亚肼基]乙基}香豆素

在微波辐射下,以酸性离子液体甲基咪唑丙磺酸-三氟乙酸为催化剂,利用一锅法由乙酰香豆素、氨基硫脲和α-溴代芳乙酮三组分反应合成了系列3-{1-[2-(4-芳基噻唑-2-基)亚肼基]乙基}香豆素,反应时间短,操作简便,收率高(85%～95%),催化剂可回收循环使用,对环境友好.     

3-(2'-苯基-1', 2', 3'-连三唑-4'-基)-6-烷基/芳基-均三唑并[3, 4-b]-1, 3, 4-噻二唑的合成

研究了3-(2'-苯基-1', 2', 3'-连三唑-4'-基)-4-氨基-5-巯基-1, 2, 4-三唑(1)与取代苯甲酸和脂肪酸(2a-r)在POCl3催化下的反应, 共合成得到18个新的3-(2'-苯基-1', 2', 3'-连三唑-4'-基)-6-烷基/芳基-均三唑并[3, 4-b]-1, 3, 4-噻二唑(3a-r), 经元素分析,IR, 1H NMR和MS进行了结构确证。     

3, 6-二取代-均三唑并[3, 4-b]-1, 3, 4-噻二唑的合成

研究了2-苯基-1, 2, 3-三唑-4-羧酸(1)与3-烷基/芳基-4-氨基-5-巯基-1, 2, 4-三唑(2a～o)在POCl~3催化下, 脱水缩合得到15个新的3-烷基/芳基-6-(2'-苯基-1', 2', 3'-三唑-4'-基)均三唑并[3,4-b]-1, 3, 4-噻二唑类化合物(3a～o)。     

3,3-二{2,2-二[4-(N,N-二取代氨基)苯基]乙烯基}-4,5,6,7-四氯-2-苯并[c]呋喃酮的合成

在对甲苯磷酸存在下,采用1,1-二[4-(N,N-二取代氨基)苯基]乙烯(3)和四氯苯酐在乙酸酐溶液中的缩合反应合成了3,3-二{2,2-二[4-(N,N-二取代氨基)苯基]乙烯基}-4,5,6,7-四氯-2-苯并[c]呋喃酮(4),产率89～93％。3由4,4＇-二(N,N-二取代氨基)二苯甲酮(1)与甲基碘化镁进行Grignard反应的产物经水解再脱水制得,产率85％～88.5％(以1为基准)。     

Studies on the esterifications of 9-（hydroxyimino）-4-methyl-8,9-dihydrofuro[2,3-h]chromen-2-one with acid chlorides under different conditions

The esterifications of 9-（hydroxyimino）-4-methyl-8,9-dihydrofuro[2,3-h]chromen-2-one （4） with acid chlorides afforded normal oxime-esters 3a-e in 35-78% yields in presence of excessive 4-dimethylaminopyridine as the acid scavenger, whereas the reactions gave unexpected 8-substituted products N-（8-chloro-4-methyl-2-oxo-2H-furo-[2,3-h]chromen-9-yl）amides （5a-c） and 4-methyl-2,9-dioxo-8,9-dihydro-2H-furo[2,3-h]chromen-8-ylcarboxyloates （6d-e） by using excessive acid chlorides. The structures of 10 new compounds were determined by 1H NMR, 13C NMR, MS and HRMS, and the possible mechanism for the formation of unexpected products 5a--c and 6d-e was also proposed.     

A highly enantioselective synthesis of 5-(l-menthyloxy )-4-substituted-3-chloro-2(5H )-furanones

In this paper, stereocontrolled tandem Michael addition-elimination reaction of the novel chiral source, 5-(l-menthyloxy)-3,4-dichloro-2(5H)-furanone, with various thiols and amines has been investigated. A series of new enantiomerically pure compounds, 5–(l-menthyloxy)-4-substituted-3-chloro-2(5H)-furanones, were obtained in good yields with d. e. ? 98% under mild conditions.     

Synthesis and Crystal Structure of Ethyl 3-（4-Chlorophenyl）-3,4-dihydro-6-methyl-4-oxo-2- （pyrrolidin-1-yl）furo[2,3-d]pyrimidine-5-carboxylate

The crystal structure of the title compound ethyl 3-（4-chlorophenyl）-3,4-dihydro-6- methyl-4-oxo-2-（pyrrolidin-1-yl）furo[2,3-d]pyrimidine-5-carboxylate （C20H20ClN3O4, Mr= 401.84） has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/n with a = 20.6215（9）, b = 8.5311（4）, c = 21.6886（9） A^°, β = 91.607（1）°, V = 3814.0（3）A^°^3, Z = 8, Dc = 1.400 g/cm^3, F（000） = 1680, μ = 0.233 mm^-1, R = 0.0718 and wR = 0.1545 for 6717 observed reflections with I 〉 2σ（I）. X-ray diffraction analysis reveals two crystallographically independent molecules in the asymmetric unit.     

A Convenient Preparation of 2-(2-Arylidene)- and 2-(2-Polyhydroxyalkylidene)hydrazono-4-imidazolidinones with Various Heterocyclic Side Chain Substituents at Position 5 as Potential Antiviral and Antitumor Agents

A variety of novel 5-[( Z )-arylidene]-2-[(2-( E )-arylidene)hydrazono]-4-imidazolidinones 1a-c to 4a , b and 5-[( Z )-arylidene]-2-[(2-( E )-polyhydroxyalkylidene)hydrazono]-4-imidazolidinones 5a-c to 7a-c were prepared from the reaction of 5-[( Z )-arylidene]-2-methylmercaptohydantoins 8a-c with 2-( E )-arylidene hydrazones 13a-d and/or 2-( E )-monosaccharides hydrazones 16a-c . The linear structure, and not that of the angular isomer, has been selected for the products. This structure has been confirmed from a model study of the condensation of 5-[( Z )-2-thienylidene]-2-hydrazono-4-imidazolidinone 9a with benzaldehyde and D -galactose, respectively. The acetylation and benzoylation reactions of compounds 1-7 have been studied. All the new compounds were tested for their potential antiviral and antitumor activities.     

Preparation of 3-Aryl-4-(5-ARYL-Δ2-1,2,4-Oxadiazolin-3-YL)Sydnones and their Conversion into 3-ARYL-4-(5-ARYL-1,2,4-Oxadiazol-3-YL)Sydnones

3-Aryl-4-(5-aryl-Δ²-1,2,4-oxadiazolin-3-yl)sydnones (5) were synthesized in high yields by the reaction of 3-arylsydnone-4-carboxamide oximes (prepared from the corresponding 3-arylsydnone-4-carbonitriles) with aromatic aldehydes in the presence of acid catalysts. No reaction occurred when aliphatic aldehydes were used. The oxadiazolin-3-ylsydnones (5) were easily converted into the corresponding 3-aryl-4-(5-aryl-1,2,4-oxadiazol-3-yl)sydnones by N-bromosuccinimide oxidation. The 3-arylsydnone-4-carbonitrile oxides were synthesized in good yields by N-bromosuccinimide oxidation of the corresponding 3-arylsydnone-4-carboxaldehyde oximes.     

HIV-1 RT抑制剂研究I.1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶的合成

报道了1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶的合成新方法.以6-甲基尿嘧啶(1)为起始物,经1,3-二苄基-6-甲基尿嘧啶(2)及未见文献报道的1,3-二苄基-6-(3-丁烯基)尿嘧啶(3)和1,3-二苄基-6-(3-羟基-4-溴丁基)尿嘧啶(4),首次高收率合成了1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶(5),并对其化学结构进行了表征.     

2,5-二取代基-1,3,4-噁二唑及噁二唑啉类化合物的合成

2-苯基-1,2,3-连三唑-4-甲酰肼(1)与芳酸在POCl_3催化下得到6种新的2-芳基-5-(2’-苯基-1’,2’,3’-连三唑-4’-基)-1,3,4-噁二唑(2)。1与羰基化合物缩合得到相应的酰腙(3),在Ac_2O作用下环化成2-取代基-3-乙酰基-5-(2’-苯基-1’,2’,3’-连三唑-4’-基)-1,3,4-噁二唑啉(4)。化合物的结构经元素分析,IR,~1H NMR和MS确证。